INTERCEPT-treated Red Blood Cells

**INTERCEPT-treated Red Blood Cells** are pathogen-reduced red blood cell components produced using the INTERCEPT Blood System, which employs amustaline (a nucleic acid-targeting alkylating agent) and glutathione to inactivate a broad spectrum of pathogens (viruses, bacteria, protozoa) and leukocytes in leukoreduced RBCs stored in AS-1 additive solution for up to 35 days at 1-6°C. The process includes a terminal media exchange that reduces plasma proteins, meeting standards for washed RBCs, potentially lowering risks of allergic reactions and TRALI while preventing transfusion-associated graft-versus-host disease (TA-GVHD) as an alternative to gamma irradiation. Developed by Cerus Corporation, it is in late-stage clinical development in the US (Phase 3 trials like ReCePI in cardiac surgery patients and recovery/lifespan studies) and under regulatory review in Europe (CE Mark pending), with demonstrated comparable in vitro/in vivo viability, recovery, and safety to conventional RBCs in studies for transfusion support in anemia, sickle cell disease, thalassemia, and regions with high TTI risk.[1][2][3][4][5][10]

Other names

INTERCEPT RBCsIBS RBCsRBCs prepared with the INTERCEPT Blood System for Red Blood Cells